CLDX News 14.04 04/26/2014 00:30:18 Celldex Therapeutics Inc

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celldex Therapeutics Inc (CLDX) 14.04 $CLDX

Celldex Therapeutics Has Returned 36.7% Since SmarTrend Recommendation (CLDX)
Comtex SmarTrend(R) - Wed Apr 23, 9:12AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 1 month, Celldex Therapeutics has returned 36.68% as of today's recent price of $15.71.

First Week of CLDX June 21st Options Trading
DividendChannel.com - Tue Apr 22, 11:55AM CDT
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the June 21st expiration.

Celldex's Phase 1 Study of CDX-1401 Published in Science Translational Medicine
GlobeNewswire - Wed Apr 16, 1:49PM CDT
--First clinical study to demonstrate that an off-the-shelf vaccine targeting dendritic cells can safely lead to robust humoral and cellular immunity--

Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global

44.7% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Tue Apr 15, 4:44PM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 1 month, Celldex Therapeutics has returned 44.66% as of today's recent price of $13.73.

After Yesterday's Decline of 2.14%, Celldex Therapeutics Offers Investors Better Value
Comtex SmarTrend(R) - Mon Apr 14, 5:52PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $13.41 to a high of $14.67. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $13.93 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free

Celldex Therapeutics Rises 9.18% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 09, 5:10PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $15.66 to a high of $17.07. Yesterday, the shares gained 9.2%, which took the trading range above the 3-day high of $16.75 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Encouraging Pre-Clinical Data from Celldex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:40PM CDT
Celldex announced encouraging results from preclinical studies on its antibody drug conjugate, CDX-014.

Shares of CLDX Down 36.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 08, 11:03AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 4 weeks, Celldex Therapeutics has returned 35.99% as of today's recent price of $15.88.

5 Stocks Forging the Future of Breast Cancer Care
George Budwell, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Breast cancer is the second leading cause of cancer deaths among women, falling second only to lung cancer. Fortunately, the mortality rate has steadily declined since 1989, partly because of earlier detection through regular screenings and improved...

Celldex Therapeutics Establishes Preclinical Proof of Concept for New Antibody Drug Conjugate CDX-014; Data presented at AACR 2014
GlobeNewswire - Mon Apr 07, 3:00PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate (ADC) that targets the protein TIM-1 (T cell immunoglobulin and mucin domain). TIM-1 expression is upregulated in several cancers, including renal cell and ovarian carcinomas. It is associated with kidney injury and the shedding of its ectodomain is a predictive biomarker for tumor progression. TIM-1 has very restricted expression in healthy tissues, making it a promising target for antibody mediated therapy. The data were presented in a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2014.

3 Biggest Biotech Crashes in March
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but the drop in some biotech stocks was simply breathtaking . Celldex Therapeutics , Acceleron , and Newlink Genetics all tumbled more than 25% last month -- far more than the 10% drop in the ...

Are These 3 Biotechs Bad News Buys?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
March wasn't kind to many of biotech's hottest names. From Geron to Exelixis , many of biotech's most talked-about stocks suffered headache-inducing falls over the past month. Biotech's had a good run lately with the market's rise, and while...

Celldex Therapeutics to Present Antibody-Drug Conjugate CDX-014 Preclinical Proof of Concept Data at AACR 2014
GlobeNewswire - Thu Apr 03, 7:03AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate (ADC) CDX-014 will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, California, April 5-9. CDX-014 targets the protein TIM-1 (T cell immunoglobulin and mucin domain), which is upregulated in several cancers, including renal and ovarian carcinomas.

'Mad Money' Lightning Round: I Want You to Buy Costco
at The Street - Thu Apr 03, 5:00AM CDT
Cramer loves Six Flags and prefers IBM to AutoDesk.

Jim Cramer's 'Mad Money' Recap: Hope Springs Eternal
at The Street - Wed Apr 02, 7:24PM CDT
Investors are hopeful the economy is really improving, and that's why some stocks are surging again, Cramer says.

Celldex Therapeutics Shares Down 26.0% Since SmarTrend's Sell Call (CLDX)
Comtex SmarTrend(R) - Tue Apr 01, 9:43AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 3 weeks, Celldex Therapeutics has returned 26.00% as of today's recent price of $18.36.

3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos
George Budwell, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
By all accounts, biotech has had a rough week. The iShares Nasdaq Biotechnology Index is down more than 8%, and concerns over a bubble abound. Yet some companies are falling much faster than the broader sector. Are these companies becoming value...

Critical Alerts For Starbucks, Verizon Communications, Du Pont, Celldex Therapeutics, and Level 3 Communications Released By InvestorsObserver
PR Newswire - Wed Mar 26, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SBUX, VZ, DD, CLDX, and LVLT.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 40

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 48

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 41

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 96

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 242

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 98

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 41

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

Jefferies Reports Optimism for Vertiv's Future Growth Potential

Updated Category News Views 95

Jefferies Boosts Vertiv Holdings Co. Stock Outlook Recently, Vertiv Holdings Co. (NYSE: VRT), known for its vital role in digital infrastructure and continuity solutions, captured attention with its promising assessment by Jefferies, a prominent financial firm. Jefferies has initiated coverage on Vertiv with a favorable Buy rating, establishing an ambitious price target...

Continue Reading
BioAdaptives: A New Era Ahead Post-Reverse Stock Split

Updated Category News Views 212

Transforming BioAdaptives for a Brighter Future In a recent update, BioAdaptives, Inc. has provided shareholders with insights regarding a key decision that impacts its future direction. After experiencing significant growth in the number of its outstanding shares without corresponding revenue growth, management recognizes the urgent need for a strategic pivot. The...

Continue Reading
Explore Spacious Model Homes at The Timbers for Active Adults

Updated Category News Views 49

Introducing The Timbers at Everlands Lennar, a prominent name in homebuilding, is excited to announce the grand opening of new model homes at The Timbers at Everlands, an innovative community tailored for active adults. These stunning homes offer three distinct styles as well as numerous amenities that cater to comfort and lively living. A Vibrant Community for Active...

Continue Reading
Emerging Innovations in the Tire Technologies Market

Updated Category News Views 410

The Evolution of Tire Technologies in a New Era As electric vehicles (EVs) transform the world of transportation, the tire sector is witnessing a crucial revolution. Gone are the days when tires were merely black rubber circles; today, they are integral to vehicle performance, providing not just grip but also intelligence. With innovations in tire design and technology,...

Continue Reading
Streamlined Emergency Cash Options: Wizzay's New Features

Updated Category News Views 209

Introducing Wizzay's 1-Hour Payday Loans In today's fast-paced world, unexpected expenses can arise at any moment. Wizzay has rolled out a groundbreaking solution for those looking for quick access to funds: 1-hour payday loans that don't involve hard credit checks. This new program is tailored for individuals who require immediate financial assistance, with many...

Continue Reading